newsfilter
← Latest News
GlobeNewswire·

Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development

NKTX
  • Cyllene Therapeutics announced the appointment of Alyssa Levin to its Board of Directors, where she will serve as Chair of the Audit Committee.
  • Clara Cambon-Thiebaud joined the company as Vice President, Regulatory Affairs, based in New York, bringing over 15 years of global regulatory experience.
  • Céline Breda joined as Vice President, Chemistry, Manufacturing and Controls (CMC), with more than 25 years of experience in biologics manufacturing.
  • These leadership additions support Cyllene Tx's strategy to advance its lead candidate, EG110A, toward late-stage clinical development for neurogenic bladder-related incontinence.
  • EG110A is currently undergoing a Phase 1/2 study in the US for neurogenic detrusor overactivity, marking the first human trial of non-replicating HSV-1 vectors for sensory neuron-based diseases.
  • Alyssa Levin previously served as CFO of Radionetics Oncology, Nkarta, and ViaCyte, raising over $500 million in financings throughout her career.
  • Clara Cambon-Thiebaud contributed to more than 30 drug development programs from preclinical research through approval, including work at Genentech.
  • Céline Breda has extensive expertise in process development, technology transfer, and GMP manufacturing for vaccines, viral vectors, and complex biological products.
  • Cyllene Tx utilizes its HERMES platform to deliver pinpoint neurotherapeutics capable of focal transduction and selective gene expression in targeted neurons.
  • The company's non-replicating HSV-1 vector technology features a large payload capacity, potential for repeat dosing, and demonstrated clinical safety.